×

References:

*Fast average turnaround time from sample receipt to results is based on stated average turnaround times from Integra Connect data. Comparisons are against other FDA-approved liquid CGP tests as of April 2024.

1. Guardant360^® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023. 2. Guardant360^® CDx Assay Specifications. Guardant Health, Inc. Redwood City, CA. 3. Sehayek, Liquid First is Solid in Naive Non Small Cell Lung Cancer patients: Faster turnaround time with high concordance to solid Next Generation Sequencing, Frontiers in Oncology, 2022. 4. Palmero, Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Oncology Precision Oncology. 5. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Receives-EU-IVDR-Certification-for-Guardant360-CDx-Liquid-Biopsy-for-Tumor-Mutation-Profiling-Across-All-Solid-Cancers-and-Companion-Diagnostic-Indications/default.aspx 6. PubMed search September 2025.